Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amersham brachytherapy and Galil urology merge:

This article was originally published in Clinica

Executive Summary

Amersham has merged its non-core brachytherapy business with the urology operations of Galil Medical, a New York-based firm that has developed cryotherapy technology. The new US company, 75% owned by Amersham, is called Oncura, and will focus on minimally invasive prostate cancer treatment. As well as SeedNet cryotherapy products, it will supply RAPID Strand, OncoSeed, EchoSeed and TheraSeed brachytherapy seeds. Amersham's former president of the therapy business, John Jeans, is chairman, and James McGlone, ex-president of Galil Medical, is president and CEO.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT062982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel